...
首页> 外文期刊>American Journal of Surgical Pathology >Immunohistochemical markers on needle biopsies are helpful for the diagnosis of focal nodular hyperplasia and hepatocellular adenoma subtypes.
【24h】

Immunohistochemical markers on needle biopsies are helpful for the diagnosis of focal nodular hyperplasia and hepatocellular adenoma subtypes.

机译:穿刺活检的免疫组织化学标记物有助于诊断局灶性结节性增生和肝细胞腺瘤亚型。

获取原文
获取原文并翻译 | 示例
           

摘要

Phenotypic identification of focal nodular hyperplasia (FNH) and hepatocellular adenoma (HCA) subtypes using immunohistochemical markers has been developed from their molecular characteristics. Our objective was to evaluate the sensitivity of these markers in the definitive diagnosis of these lesions by core needle biopsies. A total of 239 needle biopsies paired with their surgical resection specimen (group A) or without an associated resection specimen (group B) were reviewed. Using a step-by-step algorithm after standard staining, appropriate immunostaining analyses were performed to determine the certainty of diagnosis of FNH, HNF1α-inactivated HCA, inflammatory HCA, β-catenin-activated HCA, or unclassified HCA. The diagnosis of FNH was certain or probable on routine stains in 53% of needle biopsies of group A, whereas after glutamine synthetase staining, the diagnosis was certain in 86.7% as compared with 100% on the corresponding surgical specimen (P=0.04). In needle biopsies of group A, the diagnosis of HCA was certain on routine stains in 58.6% as compared with 94.3% on surgical specimens. After specific immunostaining, diagnosis was established on biopsies with 74.3% certainty, including all HCA subtypes, with similar distribution in surgical specimens. For each "certain diagnosis" paired diagnostic test (biopsy and surgical specimen), a positive correlation was observed (P<0.001). No significant difference was observed between groups A and B for FNH (P=0.714) or for HCA subtypes (P=0.750). Compared with surgical specimens, immunohistochemical analysis performed on biopsies allowed the discrimination of FNH from HCA and the identification of HCA subtypes with good performance.
机译:从免疫分子化学标记物的分子特征出发,已开发出利用局域性结节性增生(FNH)和肝细胞腺瘤(HCA)亚型进行表型鉴定的方法。我们的目标是评估这些标记物在通过核心穿刺活检明确诊断这些病变中的敏感性。总共239针活检与他们的手术切除标本(A组)或没有相关切除标本(B组)进行了审查。在标准染色后,使用分步算法进行适当的免疫染色分析,以确定FNH,HNF1α灭活的HCA,炎性HCA,β-连环蛋白激活的HCA或未分类的HCA的诊断确定性。 A组53%的活检组织活检对FNH的诊断是肯定或可能的,而谷氨酰胺合成酶染色后,相对于相应手术标本的100%,FNH的诊断为86.7%(P = 0.04)。在A组的穿刺活检中,常规染色的HCA确诊率为58.6%,而手术标本为94.3%。经过特定的免疫染色后,可以对活检进行诊断,包括所有HCA亚型在内的活检确诊率为74.3%,在手术标本中的分布相似。对于每个“确定的诊断”配对诊断测试(活检和手术标本),观察到正相关(P <0.001)。在A组和B组之间,对于FNH(P = 0.714)或HCA亚型(P = 0.750)没有观察到显着差异。与手术标本相比,对活检组织进行的免疫组织化学分析可以区分FNH和HCA,并可以鉴定具有良好性能的HCA亚型。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号